Only about one third of patients with major depressive disorder achieve full remission with antidepressant therapy. Another third are considered nonresponders, and the remaining one third are partial responders. The latter group of patients are those who have seen some improvement but have not achieved full remission.
Dr Michael Thase at the Perelman School of Medicine, University of Pennsylvania, discusses the symptomatic burden and risk for relapse faced by partial responders, who present a significant treatment challenge.
Dr Thase explores the therapeutic options available when a first-choice treatment option proves incompletely effective. In addition to medication optimization, adjunctive treatment and alternative approaches are considered.
--
Michael E. Thase, MD, Professor, Department of Psychiatry, Mood and Anxiety Disorders Treatment and Research Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Michael E. Thase, MD, has disclosed the following relevant financial relationships:
Serve(d) as an advisor or consultant for: Acadia, Inc; Akili, Inc;
Alkermes PLC; Allergan, Inc; Axsome Therapeutics, Inc; BioHaven, Inc; Bocemtium Consulting, SL; Boehringer Ingelheim International; CatalYm GmbH; Clexio Biosciences; Gerson Lehrman Group, Inc; H Lundbeck, A/S; Jazz Pharmaceuticals; Janssen; Johnson & Johnson; Luye Pharma Group, Ltd; Merck & Company, Inc; Otsuka Pharmaceuticals Company, Ltd; Pfizer, Inc; Sage Pharmaceuicals; Seelos Pharmaceuticals; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceutical Company, Ltd
Receive research funding from: Acadia, Inc; Allergan, Inc; AssureRx; Axsome Therapeutics, Inc; BioHaven, Inc; Intracellular, Inc; Johnson & Johnson; Otsuka Pharmaceuticals Company, Ltd; Patient-Centered Outcomes Research Institute (PCORI); Takeda Pharmaceutical Company, Ltd
Receive royalties from: American Psychiatric Foundation; Guilford Publications; Herald House; Kluwer-Wolters; W W Norton & Company, Inc